Rana Dhara, Pietrandrea Peter, Isaac Rea, Husain Ali, Rainear Kristen
Department of Internal Medicine, Inspira Medical Center Vineland, Vineland, USA.
Department of Cardiology, Deborah Heart and Lung Center, Browns Mills, USA.
Cureus. 2025 Jul 31;17(7):e89162. doi: 10.7759/cureus.89162. eCollection 2025 Jul.
Background Lambl's excrescences (LE) and cardiac papillary fibroelastomas (CPF) are valvular structures that have been associated with cryptogenic strokes, potentially acting as embolic sources or sites of thrombus formation. However, the management of LE and CPF - whether discovered incidentally or in the setting of cerebrovascular events (cardiovascular accident (CVA)/transient ischemic attack (TIA)) - remains poorly defined, with no randomized trials to guide treatment. Methods We conducted a retrospective case series at a single center from July 2018 to June 2024, identifying 10 patients with LE or CPF. Nine patients presented with CVA/TIA; one had an incidental CPF finding. All patients were followed for a minimum of six months. The cohort had a mean age of 69.4 years (range 58-79 years), and common comorbidities included hypertension (7/10), diabetes (5/10), hyperlipidemia (4/10), coronary artery disease (2/10), and chronic kidney disease (1/10). Results No alternative stroke etiology was identified in CVA/TIA cases after standard evaluation. Management strategies included direct oral anticoagulants (n=5), warfarin (n=1), dual antiplatelet therapy (n=3), and surgical valve replacement (n=1). No recurrent strokes related to LE or CPF were observed during follow-up. Two patients later experienced strokes due to progressive carotid artery stenosis. Conclusions In this small, descriptive case series, individualized management strategies for LE and CPF appeared safe over short- to mid-term follow-up. Given the absence of consensus guidelines and randomized data, further research is needed to define optimal treatment and clarify causal relationships.
背景 兰布尔赘生物(LE)和心脏乳头状纤维弹性瘤(CPF)是与隐源性卒中相关的瓣膜结构,可能作为栓子来源或血栓形成部位。然而,LE和CPF的管理——无论是偶然发现还是在脑血管事件(心血管意外(CVA)/短暂性脑缺血发作(TIA))背景下发现——仍不明确,尚无随机试验指导治疗。方法 我们于2018年7月至2024年6月在单一中心进行了一项回顾性病例系列研究,确定了10例患有LE或CPF的患者。9例患者表现为CVA/TIA;1例偶然发现CPF。所有患者至少随访6个月。该队列的平均年龄为69.4岁(范围58 - 79岁),常见合并症包括高血压(7/10)、糖尿病(5/10)、高脂血症(4/10)、冠状动脉疾病(2/10)和慢性肾脏病(1/10)。结果 标准评估后,CVA/TIA病例未发现其他卒中病因。管理策略包括直接口服抗凝剂(n = 5)、华法林(n = 1)、双联抗血小板治疗(n = 3)和手术瓣膜置换(n = 1)。随访期间未观察到与LE或CPF相关的复发性卒中。2例患者后来因颈动脉狭窄进展而发生卒中。结论 在这个小型描述性病例系列中,LE和CPF的个体化管理策略在短期至中期随访中似乎是安全的。鉴于缺乏共识指南和随机数据,需要进一步研究以确定最佳治疗方法并阐明因果关系。